We are collaborating with a number of leading researchers, clinicians and institutions these include:
Bod will be one of five companies to participate in Europe’s largest medicinal cannabis project. Based in the UK, Project Twenty21 will study the effects of cannabis when used on up to 20,000 patients suffering from chronic conditions. Project Twenty21 aims to create the largest body of evidence for the efficacy of medicinal cannabis. The initiative will use collated data to support policy makers as they review medicinal cannabis availability, and affordability for patients who would benefit from its use. The project will assist prescribers operating in private practice and advance the potential for NHS funding.
The University of Sydney
The Lambert initiative is an Australian first in the field of medicinal cannabinoids. Their aim is to optimise safe and effective cannabinoid therapeutics into mainstream medicine in Australia and beyond to deliver long overdue benefits for patients and to alleviate suffering, targeting a range of conditions including paediatric epilepsy, cancer, chronic pain, obesity, neurological, and mental health disorders.
Bod Medicinal Cannabis has been used in a number of the studies conducted
Following a three-year collaboration with University of Technology Sydney, Bod has potentially discovered a novel family of proteins found in human cells that provide antioxidant protective effects when applied to cells. Bod is of the view that these could be used topically to combat the skin ageing process.
The global anti-ageing market was worth approximately US$50.2Bn in 2018 with an estimated compound average growth rate of 5.7% through to 2023i. This represents another compelling opportunity for Bod, should it progress with commercialisation initiatives.
The proteins were found to be instrumental in protecting cells and increasing tolerance and recovery from UV light. Laboratory testing also showed increased levels of antioxidant activity, cellular growth and metabolism, furthering the protein’s cellular protective effects.
Bod will now pursue the development of a patent protected, novel anti-ageing topical application and topical delivery system. The Company retains the global rights to the delivery method, which it will commercialise or licence to a large healthcare or pharmaceutical company. Bod and UTS will continue to explore potential uses for the protein in collaboration with CBD and hemp products, as well as other cannabis compounds.
University of South Australia (UniSA)
Bod entered a collaboration to conduct further research of its full spectrum product (50mg CBD/mL). Both parties will study its effect on patients to assist in ongoing product development. It will also provide valuable information for clinical practice and future research. The collaboration will be undertaken with researchers from UniSA’s School of Pharmacy and Medical Sciences. This is a nationally renowned school that specialises in the quality use of medicines, drug development and pharmaceutical science.